Partner David Simon was quoted in an Agenda article, “SEC, DOJ to Trim FCPA Enforcement in 2017.” The article discussed how new leadership at the SEC and DOJ in 2017 may impact enforcement at both agencies, particularly as it relates to prioritization of anti-bribery and corruption compliance. In reference to Jeff Sessions as the new attorney general, Simon said Sessions is viewed as a “prosecute or don’t prosecute kind of guy.” Under Sessions’ leadership, the DOJ could take a more black-and-white approach to the FCPA, issuing fewer deferred and non-prosecution agreements over gray-area cases, he said.
The article also focused on the DOJ’s FCPA pilot program and whether it will continue under the Trump administration. Simon said that, “My optimistic side says if the new administration is trying to make this more of a pro-business paradigm, they’ll actually take it further and build more certainty in.”
The article also focused on the DOJ’s FCPA pilot program and whether it will continue under the Trump administration. Simon said that, “My optimistic side says if the new administration is trying to make this more of a pro-business paradigm, they’ll actually take it further and build more certainty in.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”